Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thermal Therapy + Immunotherapy in HER2-negative Breast Cancer with Liver Metastases
NCT07466927Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Mar 2026
- Primary completion
- Jan 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label trial of sacituzumab tirumotecan, pembrolizumab, trastuzumab rezetecan and adebrelimab in breast cancer (2 arms), sponsored by Fudan University. Primary endpoint: Progression-Free Survival at 12 months. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07466927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07466927.